Other

Suntory Limited

National Cerebral and Cardiovascular Center

Shionogi Company Limited

Daiichi Sankyo Company, Limited

University of Miyazaki

Kenji Kangawa

Takeda Pharmaceutical Company Limited

Osaka University

Kyoto University

Kabushiki Kaisha Yakult Honsha

Daiichi Pure Chemicals Co., Ltd.

Tokyo University of Pharmacy & Life Sciences

Hisayuki Matsuo

Hubit Genomix, Inc.

Hiroshi Hosoda

Masayasu Kojima

Naoto Minamino

Yoshiharu Minamitake

Takashi Nojiri

Kazuo Kitamura

Tanenao Eto

Shoji Tanaka

Atsushi Izumi

Yasunori Tawaragi

Keiko Nakahara

Noboru Murakami

Yujiro Hayashi

Tetsuji Sudoh

Kenji Mori

Mikiya Miyazato

Takashi Asahara

Keiji Maekawa

Hiroshi Nakazato

Takehiro Oshima

Akira Yamamoto

Naomi Wakabayashi

Yoshio Hayashi

Yoshiyuki Shishido

Shinzo Oikawa

Takashi Akamizu

Kayoko Fuchimura

Kentaro Takayama

Mayumi Furuya

Yasutake Tanaka

Motofumi Kumazoe

Keisuke Taniguchi

Takahito Miura

Naoto Minamito

Toshiyasu Sakane

Meinoshin Okumura

Mika Takashima

Shuichi Koda

Taiga Irako

Mitsutaka Isogai

Kunio Miyatake

Shinsuke Murakami

Noritoshi Nagaya

An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.

Antitumor effect potentiator

The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of amino acid sequences represented by SEQ ID NOS: 1 to 22, or an amino acid sequence in which one to several amino acids are deleted, substituted or added at the amino acid residues other that the first to forth amino acid residues from the amino-terminus in the said amino acid sequence, or a pharmacologically acceptable salt thereof. The preventive or the therapeutic agent for hepatopathy in accordance with the present invention is useful as a drug suitable for treating or preventing hepatic diseases such as hepatitis, liver cirrhosis and hepatic insufficiency. Further, the preventive or the therapeutic agent for hepatopathy in accordance with the present invention is also useful as an agent of promoting hepatic regeneration and hepatic function recovery after hepatectomy.

Preventives or remedies for hepatopathy

To provide a peptide that selectively activates type 2 neuromedin U receptor and is chemically stable under physiological conditions. A peptide represented by Formula (1) described in the specification.

Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof

Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.

Medicament for suppressing malignant tumor metastasis

A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof.

Method for suppressing malignant tumor metastasis

The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.

Modified ghrelin peptides

An object of the present invention is to provide a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc. The present invention provides a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc., the agents etc. comprising desacyl ghrelin or its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.

Methods of lowering body temperature by administration of desacyl ghrelin or its derivative

Medicinal agent for suppressing malignant tumor metastasis

Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.

Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A and GC-B agonists

An object of the present invention is to provide a therapeutic agent for accelerating recovery to accelerate a return to normal physical conditions by administering to an animal not in good health and under medical treatment, a treatment method, and the like. There is provided a therapeutic agent for accelerating recovery for animal use to accelerate the improvement of a physical condition of an animal under medical treatment which has a decreased activity (vigor) and is exhausted, which contains ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient and improves one or more of evaluation parameters consisting of activity (vigor), blood cell test values, biochemical test values, body temperature, the degree of anger or anxiety, and respiratory rate.

Therapeutic agent for accelerating recovery of animal under medical treatment

Modified gherlin peptides

The present invention provides a variety of useful polypeptides. In particular, a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, its amide, or a salt thereof can be used as an agent for preventing/treating hypotension; an agent for preventing/treating obesity, hyperphagia, etc.; an agent for preventing/treating lethargy, time-zone change syndrome (jet lag), etc.; an agent for preventing/treating sterility, etc. A compound or its salt that promotes the activity of a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by any of SEQ ID NOS: 7 to 12 and 37 to 42, its partial peptide, or a salt thereof is useful as an agent for preventing/treating, e.g., menopausal symptoms or hyperthyroidism. A compound or its salt that inhibits the activity of said polypeptide is useful as an agent for preventing/treating, e.g., sterility or hypothyroidism.

Polypeptide and the use thereof

A pharmaceutical for promoting neogenesis or regeneration of pancreatic &#x3b2; cells which produces and secretes insulin and for promoting insulin production in &#x3b2; cells, comprising ghrelin or a derivative thereof as an effective component.

Method for treatment of hyperglycemia in a subject in need thereof

Growing community of inventors

Osaka, Japan

Kenji Kangawa